Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $47.1 million.

  • Arcutis Biotherapeutics' Cash & Equivalents fell 65.06% to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.1 million, marking a year-over-year decrease of 65.06%. This contributed to the annual value of $71.3 million for FY2024, which is 19.30% down from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Cash & Equivalents of $47.1 million as of Q3 2025, which was down 35.22% from $72.7 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Cash & Equivalents high stood at $288.7 million for Q1 2021, and its period low was $47.1 million during Q3 2025.
  • Its 3-year average for Cash & Equivalents is $94.2 million, with a median of $84.3 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 75.82% in 2022, then skyrocketed by 133.52% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Cash & Equivalents (Quarterly) stood at $96.4 million in 2021, then tumbled by 44.38% to $53.6 million in 2022, then soared by 64.80% to $88.4 million in 2023, then dropped by 19.30% to $71.3 million in 2024, then tumbled by 65.06% to $47.1 million in 2025.
  • Its Cash & Equivalents was $47.1 million in Q3 2025, compared to $72.7 million in Q2 2025 and $53.1 million in Q1 2025.